Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ: XNCR )

10.57 -0.27 (-2.49%)
Streaming Delayed Price Updated: 1:34 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 190,262
Open 10.67
Bid (Size) 10.54 (3)
Ask (Size) 10.56 (2)
Prev. Close 10.84
Today's Range 10.26 - 10.67
52wk Range 7.160 - 27.24
Shares Outstanding 59,924,016
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xencor Appoints Todd Simpson to Board of Directors
From Xencor, Inc.
Via Business Wire
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
From Xencor, Inc.
Via Business Wire

Performance

YTD
-55.57%
-55.57%
1 Month
-10.58%
-10.58%
3 Month
-48.34%
-48.34%
6 Month
-50.05%
-50.05%
1 Year
-44.43%
-44.43%

More News

Read More
Eliminating Some Screened Stocks
Via Talk Markets
Topics Stocks / Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Critical Insights From Xencor Analyst Ratings: What You Need To Know
Via Benzinga
Xencor Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Decoding 5 Analyst Evaluations For Xencor
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor Reports Third Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
Peeling Back The Layers: Exploring Xencor Through Analyst Insights
Via Benzinga
Decoding 6 Analyst Evaluations For Xencor
Via Benzinga
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
From Xencor, Inc.
Via Business Wire
Xencor Announces Upcoming Change to Board of Directors
From Xencor, Inc.
Via Business Wire
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Xencor, Inc.
Via Business Wire
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
From Xencor, Inc.
Via Business Wire
Xencor Announces Proposed Public Offering of Common Stock
From Xencor, Inc.
Via Business Wire
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
From Xencor, Inc.
Via Business Wire
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
From Xencor, Inc.
Via Business Wire
XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Xencor Reports Second Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
From Xencor, Inc.
Via Business Wire
XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Xencor Reports First Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.